Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31323701 | 0.79 | PREP (0.57) | PREPSMN1; SMN2NPC1RAB9AKLK7 | |
| SCHEMBL7318776 | 0.78 | PREP (0.55) | PREPSMN1; SMN2NPC1RAB9AKLK7 | |
| SCHEMBL7312769 | 0.78 | PREP (0.55) | PREPSMN1; SMN2NPC1RAB9AKLK7 | |
| SCHEMBL7312764 | 0.78 | PREP (0.55) | PREPSMN1; SMN2NPC1RAB9AKLK7 | |
| SCHEMBL10310509 | 0.77 | PREP (0.50) | PREPKLK7KLK5ACE2HSD17B10 | |
| SCHEMBL25759347 | 0.77 | PREP (0.50) | PREPKLK7KLK5ACE2HSD17B10 | |
| SCHEMBL21193181 | 0.76 | PREP (0.54) | PREPACE2NPSR1TSHR | |
| SCHEMBL15817600 | 0.76 | PREP (0.58) | PREPSMN1; SMN2NPC1RAB9AKLK7 | |
| SCHEMBL9873062 | 0.76 | PREP (0.83) | PREPSMN1; SMN2NPC1RAB9AKLK7 | |
| SCHEMBL26130329 | 0.76 | PREP (0.47) | PREPSMN1; SMN2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192614-A1 | METHOD FOR PREPARATION OF TRANS-N-BENZYLOXYCARBONYL-(3-HYDROXY-2-PIPERIDINYL)-2-PROPANONE AS INTERMEDIATE OF HALOFUGINONE | CHENGDA PHARMACEUTICALS CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192614-A1 | METHOD FOR PREPARATION OF TRANS-N-BENZYLOXYCARBONYL-(3-HYDROXY-2-PIPERIDINYL)-2-PROPANONE AS INTERMEDIATE OF HALOFUGINONE | TALDO1, RPL22, RPS20 | PREP 1233/4885SMN1; SMN2 3272/4885NPC1 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.